Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for
@GreatDebatesCME
and
@LLMCongress
.
Ghassan Abou-Alfa, MD, MBA,
@GABOUALFA
discusses the results from the ClarIDHy trial, which evaluated ivosidenib in IDH1-mutant advanced cholangiocarcinoma. Watch here:
Here, Paolo Tarantino, MD, discusses discoveries made in the genomic characterizations and treatment of HER2-low, HER2-zero, and HER2-positive breast cancers, which he presented at the San Antonio Breast Cancer Symposium.
@DanaFarber
@PTarantinoMD
#SABCS
Dr. Shaji Kumar,
@myelomaMD
, from
@MayoClinic
, discusses MRD testing, its use in standard practice, and how this testing affects the treatment decision-making process for patients with
#myeloma
.
John Strickler, MD,
@DukeCancer
, discusses an analysis of the phase 2 MOUNTAINEER trial, in which tucatinib plus trastuzumab demonstrated clinically meaningful antitumor activity in metastatic
#colorectalcancer
.
@ESMOWorldGI
#WCGIC2022
Watch the video:
Here, Betty K. Hamilton, MD, discusses the findings of a pilot trial analyzing patient-reported outcomes for the management of patients with acute graft-versus-host-disease (
#GVHD
). Follow along here:
@hamiltkyb
@ClevelandClinic
At the 2023 World Congress on Gastrointestinal Cancers James Harding, MD, presented data from the first-in-human phase 1 study of LY3410738. Learn more here:
#onctwitter
#medtwitter
#cholangiocarcinoma
Round 1 is now live! Listen as
@JTrentMDPhD
and
@DrRobinLJones
go head-to-head on whether the quality of evidence sufficiently supports the use of adjuvant/neoadjuvant chemotherapy for localized soft-tissue
#sarcoma
. Moderated by
@bvantine1
.
#Debate
In a recent podcast,
@gregoryjaune
, from
@UTHealthSA
, discusses his team’s findings from a multicenter study evaluating the long-term risk for anthracycline-related cardiomyopathy in survivors of childhood
#cancer
. Listen here:
Minouk Schoemaker, PhD, from
@ICR_London
, discusses the origin of the Premenopausal Breast Cancer Collaborative Group and the outcomes of their latest study examining the relationship between BMI and the risk for
#breastcancer
in premenopausal women.
At
#WorldGI2019
, Margaret Tempero, MD, presents, for the first time, results from the phase 3 RESOLVE trial, which assessed the safety & efficacy of ibrutinib plus nab-paclitaxel/gemcitabine in pancreatic cancer. Visit our newsroom for exclusive coverage:
At
#GDUHem
@JoshuaRichterMD
discussed promising novel advances in the multiple myeloma treatment landscape, including the use of t-cell redirection therapy and possible treatment approvals to come. Learn more:
#medtwitter
#onctwitter
Here, Philip Philip, MD, defended the position of doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma at the 2023 World Congress on Gastrointestinal Cancers. Learn more:
#medtwitter
#onctwitter
#WCGIC2023
#GIoncology
ICYMI: OLN interviewed Joshua Bauml, MD,
@Jbauml
on the results and significance of the first trial combining Immunotherapy and LAT for Oligometastatic NSCLC.
#nsclc
Check it out here:
Dr Abou-Alfa,
@GABOUALFA
,
@sloan_kettering
, discusses novel therapies and why
#etiology
is important in the treatment of hepatocellular
#carcinoma
in the second part of this interview during the virtual 2020
@ASCO
Annual Meeting.
Watch Here:
Follow along as Claire Harrison, MD, leads a discussion on
#PolycythemiaVera
and the importance of hematocrit control with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD, in the first installment of a 4-part expert roundtable series.
@jjkiladjian
Here,
@OmidHamidMD
discussed results from a trial examining the combination treatment of fianlimab plus cemiplimab for patients with advanced melanoma, as presented at the 2023
@ASCO
annual meeting. Learn more:
#medtwitter
#onctwitter
#fianlimab
At the 2023
@ASCO
annual meeting, Emily C. Liang, MD, shared data on the long-term outcomes of patients treated in a phase 1 and 2 clinical trial of CD19-targeting CAR T-cell therapy for R/R chronic lymphocytic leukemia
#CLL
. Learn more here:
@emilyliangmd
Episode 4 of our 7 part web series is now available: COVID-19 & Hematologic Malignancies: Effective Management & Patient Experience from Seattle to Chicago. This is a free, accredited activity. Watch here:
First trial combining Immunotherapy and LAT for Oligometastatic NSCLC yields intriguing results. Joshua Bauml, MD,
@Jbauml
discusses the significance with OLN here:
In this interview with OLN, Dr Xiao Xu,
@YaleMed
talks about power morcellation at the time of hysterectomy/myomectomy and the associated mortality risk in occult uterine cancer. Read more here:
A wonderful discussion at
#WorldGI2019
between
@GABOUALFA
, Dr Arndt Vogel, and Dr Chris Verslype, about the REACH/REACH-2 clinical trial. Coming soon! View this video and more:
Othman Al-Sawaf, MD, University Hospital of Cologne, Germany,
@UKKoeln
,
discusses highlights from the phase 3 CLL14 trial, which looked at
#venetoclax
plus
#obinutuzumab
therapy for CLL.
Watch Here:
What's New in Anal Cancer over the Last 12 Months?
@CathyEngMD
, MD, FACP, FASCO, discussed the latest developments in anal cancer over the past 12 months with OLN at
@WCGIC
. You can watch now here:
Round 2, moderated by
@bvantine1
, is now live! Listen as
@JTrentMDPhD
and
@DrRobinLJones
#debate
whether the benefits of adjuvant/neoadjuvant chemotherapy in soft-tissue
#sarcoma
outweigh the associated toxicities. Who do you think won this round?
Here, Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of
#mosunetuzumab
monotherapy among patients with relapsed/refractory follicular lymphoma
#FL
. Learn more:
@DrMatasar
@RutgersCancer
#MedTwitter
Now Available: Access meeting materials, including educational presentations, abstracts, posters, and livestreams from
#LymphomaMyeloma2018
@LMCongress
At the 2023 Great Debates and Updates in Gastrointestinal Malignancies
#GDUGI
meeting, Cathy Eng, MD, offered her perspectives on the current and upcoming clinical trials for treatments of anal cancer. Learn more:
@GreatDebatesCME
@CathyEngMD
In this video, Matthew Matasar, MD, discusses upcoming studies and encouraging advances that show promise in the continually evolving treatment landscape for patients with follicular lymphoma
#FL
. Learn more:
@DrMatasar
@RutgersCancer
#MedTwitter
New: Free online CME activity: COVID-19 & Hematologic Malignancies. Episode 1 of this 6 part series will cover effective management from the east to west coast. Watch here:
ICYMI: Shwetal Mehta, PhD,
@IvyBrainTumCtr
talks about the clinical significance of a study evaluating the use of ribociclib in patients with recurrent glioblastoma. Check out the interview:
Andrea Sartore Bianchi, MD,
@andrea_sart
sat down with OLN to discuss the HER2 Pathway in gastrointestinal cancer at the 2019
@ESMO
World Congress on Gastrointestinal Cancer
@WCGIC
Watch the video here:
In this short podcast with OLN,
@DrDawnHershman
, MD, MS, discusses how the cost of breast cancer treatment is directly tied to therapy adherence. Listen here:
At the 2020 Great Debates and Updates in Hematologic Malignancies Meeting
@GreatDebatesHem
, Peter Voorhees, MD, debated Joseph Mikhael
@jmikhaelmd
, MD, Med, FRCPC, on the best approach to treating
#patients
with smoldering
#myeloma
.
Watch Here:
Sattva Neelapu, MD,
@MDAndersonNews
, discusses early results from the ALPHA study suggesting that ALLO-501 and ALLO-647 are safe and may be effective in LBCL and FL.
Watch Here:
In the 3rd installment of a 4-part expert roundtable series, Claire Harrison, MD, leads a discussion on how to determine when first-line
#PolycythemiaVera
therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
@jjkiladjian
In this video, Dr Wang,
@michaelwangmd
,
@MDAndersonNews
, discusses the use of LOXO-305, a highly selective BTK inhibitor, in patients with pretreated MCL, WM, and other NHLs.
Watch Here:
In the first installment of this 3-part podcast series,
@DrJFriedberg
, from
@WilmotCancer
, discusses the current barriers to care for patients with aggressive lymphoma.
Experts detect gene that prevents immunotherapy from destroying cancer cells. OLN interviewed Robert K. Bradley, PhD,
@bradleybio
and Stephen J. Tapscott, MD, PhD
@fredhutch
about their findings, you can read the interview here:
In the 2nd installment of a 4-part expert roundtable series, Claire Harrison, MD, leads a discussion on
#PolycythemiaVera
, aims of treatment, and choice of first-line therapy with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
@jjkiladjian
According to Ignace Vergote, MD, and coauthors "a preliminary analysis of a prespecified exploratory subgroup of patients with TP53wt [endometrial cancer] showed promising results with selinexor maintenance therapy.” Learn more:
#medtwitter
#onctwitter
Have you seen our interview with Ruben Mesa, MD, from
@MaysCancer
? Here,
@mpdrc
discusses the ongoing phase II study of luspatercept in subjects with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Episode 6 of our 7 part web series is now available: COVID-19 & Hematologic Malignancies: Myeloid Malignancy Update with
@jmikhaelmd
and
@jaltmanmd
. This is a free, accredited activity. Watch here:
Follow along as
@EmilyBaumrinMD
, discusses her research on whether the severity of skin involvement of chronic graft-versus-host-disease is a prognostic marker for poorer outcomes in patients with chronic graft-versus-host-disease
#GVHD
.
@PennMedicine
In this short video, meeting chair,
@jmikhaelmd
, shares his insight on relapsed
#myeloma
, why he chose to practice in oncology, and why he's looking forward to the 2019 Great Debates and Updates in Hematologic Malignancies meeting series.
@GreatDebatesHem
The final episode of our 7-part series is now available: COVID-19 & Hematologic Malignancies: Infectious Disease Update with
@jmikhaelmd
and Dr. Michael Satlin. This is a free, accredited activity. Watch here:
Episode 5 of our 7 part web series is now available: COVID-19 & Hematologic Malignancies: Patient Experience Update with
@jmikhaelmd
and
@yelakbiru
. This is a free, accredited activity. Watch here:
In a panel moderated by
@EileenMOReilly
, Drs Golan, Hammel, and Macarulla discuss the POLO trial, which assessed the safety and efficacy of maintenance olaparib in metastatic pancreatic cancer. Visit to view this video and more from
#WorldGI2019
At the 2019 ESMO Congress, Amer Zeidan, MBBS, discussed Onvansertib in combination with standard-of-care chemotherapy as safe, well-tolerated in AML.
#ESMO19
#AML
#lymphoma
Watch now:
At
@ESMO
@WCGIC
, our expert roundtable consisting of
@GABOUALFA
, MD; Arndt Vogel, MD, PhD; and Chris Verslype, MD, PhD, FACP, discussed the clinical significance of the REACH and REACH-2 clinical trials.
#ESMO
#WorldGI
Watch the full discourse here:
Loretta Nastoupil, MD,
@MDAndersonNews
, discusses results from a study exploring obinutuzumab therapy plus lenalidomide in patients with untreated, high tumor burden FL.
#lymphoma
Watch here:
According to Muhammad Bilal Abid, MD, "Younger matched unrelated donors should be preferred over older matched sibling donors whenever both are available." Follow along as
@BilalAbidMD
shares more of his insights!
@MedicalCollege
Ghassan Abou-Alfa, MD,
@GABOUALFA
,
@sloan_kettering
, discusses systemic and local therapy updates in hepatocellular carcinoma in the third part of this interview highlighting abstracts of note presented at the 2020
@ASCO
Annual Meeting.
Watch Here:
“This final analysis of ATEMPT confirms the outstanding efficacy of T-DM1 at preventing recurrences of stage I HER2-positive breast cancer,” concluded
@PTarantinoMD
, et al. Learn more:
#medtwitter
#onctwitter
Dr. Zeidan
@Dr_AmerZeidan
discusses results from a phase 2 study exploring azacitidine plus durvalumab in older patients with
#AML
and high-risk
#MDS
in this quick interview with OLN. Watch here:
In this 3-part podcast series, Gabriela Hobbs, MD, Clinical Director
@MassGeneralNews
, discusses the current therapies available for patients with chronic myeloid leukemia, and what the future outlook is for the treatment landscape of this disease.
According to results from the phase 3 GETUG-AFU-18 study, combined dose-escalated radiotherapy and long-term ADT improved bcPFS and survival outcomes among patients with high-risk prostate cancer. Learn more:
#medtwitter
#onctwitter
#GU24
#ASCOGU